X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Partnering with leading engineered cell therapy developers is a key component of Arbor’s strategy to broaden the potential of CRISPR discovery engine beyond the wholly-owned in vivo genetic medicine approaches for the benefit of even more patients.
Lead Product(s): Ex-vivo Engineered Cell Therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: EdiGene
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 08, 2022
Details:
The combined company, operating as Azurity, will have a portfolio of products serving the unmet needs of patients in the cardiovascular, central nervous system, endocrinological, gastrointestinal, and institutional markets with many products like Epaned.
Lead Product(s): Enalapril Maleate
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Epaned
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Azurity
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition August 24, 2021
Details:
The Phase 3 data being presented support Arbor’s New Drug Application (NDA) for AR19, which also includes data demonstrating that AR19 resists manipulation for nonmedical misuse and abuse by non-oral routes of administration.
Lead Product(s): Amphetamine
Therapeutic Area: Psychiatry/Psychology Product Name: AR19
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
